|
Abbreviated name: BTLA
Synonyms: B- and T-lymphocyte attenuator | B- and T-lymphocyte-associated protein | CD272
Compound class:
Endogenous peptide in human, mouse or rat
Comment: BTLA is a negative immunomodulator. Interaction of BTLA with TNFRSF14 (HVEM) constitutes an immune checkpoint which inhibits T cell-mediated immune responses. Dysregulated BTLA expression contributes to immunosuppression and progression of some cancers [1-4] by enabling tumour immune evasion. Immunotherapeutics that target the BTLA-HVEM checkpoint offer potential as anti-tumour agents [5-6].
Species: Human
|
| References |
|
1. Hu X. (2024)
The role of the BTLA-HVEM complex in the pathogenesis of breast cancer. Breast Cancer, 31 (3): 358-370. [PMID:38483699] |
|
2. Kong X, Zhang J, Chen S, Wang X, Xi Q, Shen H, Zhang R. (2024)
Immune checkpoint inhibitors: breakthroughs in cancer treatment. Cancer Biol Med, 21 (6): 451-72. [PMID:38801082] |
|
3. Miyashita H, Bevins NJ, Thangathurai K, Lee S, Pabla S, Nesline MK, Glenn ST, Conroy JM, DePietro P, Rubin E et al.. (2024)
The transcriptomic expression pattern of immune checkpoints shows heterogeneity between and within cancer types. Am J Cancer Res, 14 (5): 2240-2252. [PMID:38859855] |
|
4. Ries J, Trumet L, Hahn A, Kunater L, Lutz R, Geppert C, Kesting M, Weber M. (2024)
The Immune Checkpoint BTLA in Oral Cancer: Expression Analysis and Its Correlation to Other Immune Modulators. Int J Mol Sci, 25 (12). [PMID:38928307] |
|
5. Wojciechowicz K, Kuncewicz K, Rutkowski J, Jassem J, Rodziewicz-Motowidło S, Wardowska A, Spodzieja M. (2024)
Targeting BTLA with the peptide inhibitor HVEM(14-39) - A new way to restore the activity of T cells in melanoma. Biomed Pharmacother, 175: 116675. [PMID:38733770] |
|
6. Wojciechowicz K, Spodzieja M, Wardowska A. (2024)
The BTLA-HVEM complex - The future of cancer immunotherapy. Eur J Med Chem, 268: 116231. [PMID:38387336] |
